RCDOF yields 0.80% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 5
Combined, RCDOF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RCDOF + JNJ for your $10,000?
Ricardo plc provides engineering, technical, environmental, and strategic consultancy services in the United Kingdom, Europe, North America, China, rest of Asia, Australia, and internationally. It operates through five segments: Energy and Environment (EE), Rail, Automotive and Industrial (A&I), Defense, and Performance Products (PP). The EE segment provides industry-leading analysis, advice, and data to governments, public agencies, and private businesses. The Rail segment offers technical advice and engineering services, and accredited assurance services. The A&I segment engages in the provision of clean, efficient, integrated propulsion, and energy solutions in area of hybrid and electric systems, electrification, engines, driveline and transmissions, testing, and vehicle engineering for automotive, aerospace, defense, energy, off-highway and commercial, marine, motorcycle and light-personal transport, and rail markets. The Defense segment focuses on engineering services, software, and products that protect life and enhance the operation, maintenance, and support of complex systems, as well as offers various engineering programmes; and anti-lock braking system/electronic stability control systems. The PP segment manufactures and assembles niche high-quality components, prototypes, and complex products, including engines, transmissions, and other precision and performance-critical products; and provides software solutions for motorsport, automotive, aerospace, defense, and rail markets. It serves transport operators, manufacturers, energy companies, financial institutions, government agencies, and non-governmental organizations. Ricardo plc was founded in 1915 and is headquartered in Shoreham-By-Sea, the United Kingdom.
Full RCDOF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.